These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34093026)

  • 1. Clinical Efficacy of Polymyxin B in Patients Infected with Carbapenem-Resistant Organisms.
    Lu Q; Li GH; Qu Q; Zhu HH; Luo Y; Yan H; Yuan HY; Qu J
    Infect Drug Resist; 2021; 14():1979-1988. PubMed ID: 34093026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety.
    Qu J; Qi TT; Qu Q; Long WM; Chen Y; Luo Y; Wang Y
    Infect Drug Resist; 2022; 15():1205-1218. PubMed ID: 35345474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant
    Chang K; Wang H; Zhao J; Yang X; Wu B; Sun W; Huang M; Cheng Z; Chen H; Song Y; Chen P; Chen X; Gan X; Ma W; Xing L; Wang Y; Gu X; Zou X; Cao B
    Front Med (Lausanne); 2022; 9():772372. PubMed ID: 35755062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections.
    Lu Q; Zhu HH; Li GH; Qi TT; Ye LJ; Teng XQ; Qu Q; He GF; Qu J
    Front Med (Lausanne); 2021; 8():620885. PubMed ID: 33634151
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study.
    Zhang X; Qi S; Duan X; Han B; Zhang S; Liu S; Wang H; Zhang H; Sun T
    J Transl Med; 2021 Oct; 19(1):431. PubMed ID: 34656132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China.
    Li L; Huang X; Liu J; Li C; Lin Z; Ren R; Zhang Y; Ding H; Chen J; Mao Y
    Infect Drug Resist; 2024; 17():3057-3071. PubMed ID: 39050834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections.
    Xia GL; Jiang RL
    BMC Infect Dis; 2021 Oct; 21(1):1034. PubMed ID: 34607561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrotoxicity and Efficacy Assessment of Polymyxin B Use in Renal Transplant Patients.
    Wen YX; Qu Q; Long WM; Luo Y; Zhuang HH; Teng XQ; Qu J
    Infect Drug Resist; 2022; 15():275-283. PubMed ID: 35115795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial.
    Liu S; Wu Y; Qi S; Shao H; Feng M; Xing L; Liu H; Gao Y; Zhu Z; Zhang S; Du Y; Lu Y; Yang J; Chen P; Sun T
    Crit Care; 2023 Jun; 27(1):232. PubMed ID: 37312218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin B-Associated Nephrotoxicity and Its Predictors: A Retrospective Study in Carbapenem-Resistant Gram-Negative Bacterial Infections.
    Wu XL; Long WM; Lu Q; Teng XQ; Qi TT; Qu Q; He GF; Qu J
    Front Pharmacol; 2022; 13():672543. PubMed ID: 35571125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods.
    Nelson BC; Eiras DP; Gomez-Simmonds A; Loo AS; Satlin MJ; Jenkins SG; Whittier S; Calfee DP; Furuya EY; Kubin CJ
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7000-6. PubMed ID: 26324272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effect of Polymyxin B and Tigecycline to overcome Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae.
    Tian Y; Zhang Q; Wen L; Chen J
    Microbiol Spectr; 2021 Oct; 9(2):e0015221. PubMed ID: 34704782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections-A Cohort Study.
    Cai Y; Leck H; Tan RW; Teo JQ; Lim TP; Lee W; Chlebicki MP; Kwa AL
    Antibiotics (Basel); 2020 Jul; 9(8):. PubMed ID: 32726974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel decoy strategy for polymyxin resistance in
    Park J; Kim M; Shin B; Kang M; Yang J; Lee TK; Park W
    Elife; 2021 Jun; 10():. PubMed ID: 34180396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.
    John JF; Falci DR; Rigatto MH; Oliveira RD; Kremer TG; Zavascki AP
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.
    Smith NM; Lenhard JR; Boissonneault KR; Landersdorfer CB; Bulitta JB; Holden PN; Forrest A; Nation RL; Li J; Tsuji BT
    Clin Microbiol Infect; 2020 Sep; 26(9):1207-1213. PubMed ID: 32061797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of colistin sulfate in the treatment of infections caused by carbapenem-resistant organisms: a multicenter retrospective cohort study.
    Peng D; Zhang F; Chen Y; Zhao C; Niu J; Yang J; Li Z; Chen C; Qiu S; Zhang H; Qin B; Fang X; Guo S; Liu Y; Shao H
    J Thorac Dis; 2023 Apr; 15(4):1794-1804. PubMed ID: 37197520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic activity of polymyxin B combined with vancomycin against carbapenem-resistant and polymyxin-resistant Acinetobacter baumannii: first in vitro study.
    Shinohara DR; Menegucci TC; Fedrigo NH; Migliorini LB; Carrara-Marroni FE; Maria Dos Anjos M; Cardoso CL; Nishiyama SAB; Tognim MCB
    J Med Microbiol; 2019 Mar; 68(3):309-315. PubMed ID: 30663954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant
    Fang J; Li H; Zhang M; Shi G; Liu M; Wang Y; Bian X
    Front Pharmacol; 2021; 12():780940. PubMed ID: 34955849
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.